Surface Oncology Inc. (SURF)’s Financial Results Comparing With CytomX Therapeutics Inc. (NASDAQ:CTMX)

This is a contrast between Surface Oncology Inc. (NASDAQ:SURF) and CytomX Therapeutics Inc. (NASDAQ:CTMX) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Surface Oncology Inc. 52.13M 2.94 17.66M -0.54 0.00
CytomX Therapeutics Inc. 75.10M 11.17 51.75M -1.93 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Surface Oncology Inc. -33.88% 63.7% 15.3%
CytomX Therapeutics Inc. -68.91% -65% -12.7%


The current Quick Ratio of Surface Oncology Inc. is 6.4 while its Current Ratio is 6.4. Meanwhile, CytomX Therapeutics Inc. has a Current Ratio of 5.5 while its Quick Ratio is 5.5. Surface Oncology Inc. is better positioned to pay off its short-term and long-term debts than CytomX Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Surface Oncology Inc. and CytomX Therapeutics Inc. are owned by institutional investors at 63.4% and 86.6% respectively. Surface Oncology Inc.’s share owned by insiders are 14.85%. Competitively, insiders own roughly 0.2% of CytomX Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Surface Oncology Inc. 3.47% -3.46% -14.61% -41.42% 0% -37.28%
CytomX Therapeutics Inc. 4.49% -9.59% -28.08% -39.64% -28.33% -31.69%

For the past year Surface Oncology Inc. was more bearish than CytomX Therapeutics Inc.


Surface Oncology Inc. beats CytomX Therapeutics Inc. on 7 of the 10 factors.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.